StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK) Announces FDA Approves KEYTRUDA plus LENVIMA Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
September 18, 2019 6:21 AM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
September 17, 2019 5:56 PM